Clee Medical receives CHF 150,000 from Venture Kick to develop a new era of highly targeted neurotherapies
Summary
Current neurosurgical procedures face significant hurdles due to limitations in precision imaging and real-time surgical guidance. These challenges not only affect surgical efficiency but also restrict patient outcomes and slow the integration of innovative neurotechnologies.The Geneva Wyss Center spin-off Clee Medical addresses these critical issues by developing innovative imaging and sensing technology and AI-driven navigation technology that delivers ultra-high-resolution, real-time visualization of the brain during surgery, without the need for contrast agents or radiation. Offering 300,000 more voxels per unit volume than MRI, this technology integrates with existing neurosurgical equipment and can be easily incorporated into current surgical routines.Targeting a global market valued at CHF 2.2 billion, Clee Medical is poised to redefine stereotactic and functional neurosurgery. With prestigious medical centers as key clients, the companys technology promises unprecedented accuracy, reduced surgical risk, increased operating capacity, and broader treatment possibilities. We are excited to continue and apply our learnings from the Venture Kick process to improve minimally invasive brain surgery worldwide!